For people living with Huntington’s disease, one of the biggest questions has always been whether researchers could develop a treatment that actually slows the disease instead of simply treating symptoms. This week, there was some encouraging news on that front.
Biotechnology company uniQure announced that the U.S. Food and Drug Administration(FDA) has informed the company that existing clinical trial data for its experimental gene therapy, AMT-130, may be sufficient to support an accelerated approval application. While the treatment has not been approved, the announcement could move it one step closer to patients and families who have been waiting decades for a therapy capable of slowing the progression of Huntington’s disease.
Huntington’s disease is an inherited neurological disorder caused by a mutation in the huntingtin gene. Over time, the disease damages nerve cells in the brain, leading to worsening movement problems, cognitive decline, and psychiatric symptoms. As symptoms progress, many patients become increasingly dependent on family members and caregivers for everyday activities.
Huntington’s disease is an inherited neurological disorder caused by a mutation in the huntingtin (HTT) gene. The mutation occurs when a section of DNA known as a CAG repeat is duplicated too many times. Most people have between 10 and 35 of these repeats, but individuals with Huntington’s disease typically have 36 or more. The higher the number of repeats, the more likely a person is to develop the disease, and in some cases, symptoms may begin at an earlier age. This genetic mutation causes the body to produce an abnormal form of the huntingtin protein. Over time, the protein builds up inside brain cells and interferes with their normal function. As nerve cells become damaged and die, patients gradually develop movement problems, cognitive decline, and changes in mood and behavior. Because Huntington’s disease is inherited in an autosomal dominant pattern, a child of an affected parent has a 50% chance of inheriting the mutation.
Current medications can help manage some of the symptoms associated with Huntington’s disease, but none have been proven to slow the underlying disease process. That is what makes AMT-130 different.
The therapy was designed to lower levels of the mutant huntingtin protein, the abnormal protein believed to drive much of the damage seen in Huntington’s disease. Rather than being taken as a daily medication, AMT-130 is delivered directly into specific areas of the brain during a one-time surgical procedure. Because the mutant huntingtin protein is believed to be one of the main drivers of brain cell damage in Huntington’s disease, researchers have spent years looking for ways to reduce its production. That is exactly what AMT-130 was designed to do.
According to the company, patients who received the higher dose of AMT-130 experienced a much slower rate of decline compared with similar patients who did not receive the treatment. Researchers followed participants for up to three years and evaluated changes in movement symptoms, thinking abilities, and daily functioning. The company reported approximately a 75% slowing in disease progression among patients receiving the higher dose when compared with matched external control groups. Researchers also reported encouraging trends in motor function, cognition, and everyday activities.
Part of what has made AMT-130 such a closely watched therapy is the unusual back-and-forth that has occurred between uniQure and the FDA over the past two years. Initially, there appeared to be optimism that the treatment’s early data could support an accelerated approval pathway. Huntington’s disease is a rare and fatal condition with no approved treatments that have been shown to slow disease progression, making it a candidate for regulatory flexibility under certain circumstances.
However, the FDA later expressed concerns about the strength of the evidence. One of the biggest challenges was that the study relied heavily on comparisons with external control groups rather than a large traditional placebo-controlled trial. Regulators questioned whether the available data were strong enough to clearly prove that the therapy was responsible for the slower rate of decline seen in treated patients.
The FDA subsequently suggested that additional studies, including a possible sham-surgery-controlled trial, might be needed before the therapy could move forward. That recommendation generated significant discussion within the Huntington’s community because brain surgery studies are more complicated than traditional drug trials and can present ethical concerns when patients undergo procedures without receiving the active treatment.
As additional patient follow-up data became available, the conversation appears to have shifted. According to the company, longer-term results continued to show a meaningful difference between treated patients and comparison groups. Those findings may have helped convince regulators that the existing evidence could be sufficient to support an accelerated approval application while additional studies continue.
While those results have generated excitement throughout the Huntington’s community, it is important to remember that the therapy is still under investigation. The study involved a relatively small number of participants, and researchers continue to collect long-term data to better understand the treatment’s effectiveness and safety.
The FDA’s latest feedback does not guarantee approval. Instead, it means the agency believes the available evidence may be strong enough for uniQure to formally submit an application for review. For patients and families affected by Huntington’s disease, the news represents one of the most promising developments in recent years. The question now becomes whether the FDA will ultimately determine that the available evidence is strong enough to support approval. If that happens, AMT-130 could become the first treatment shown to slow the progression of Huntington’s disease rather than simply helping patients manage symptoms.
While there is still work to be done before any final decision is made, many researchers, advocates, and families will be watching closely over the coming months. For a disease that has long had few treatment options and no proven way to slow progression, the possibility of a therapy like AMT-130 reaching patients offers something that has often been difficult to find in Huntington’s disease research: cautious optimism. niQure says the FDA has agreed that three years of data from its AMT-130 clinical trial may be enough to support an application for accelerated approval in Huntington’s disease. The FDA still wants a larger follow-up study to confirm the treatment works, and discussions about that study are ongoing. The company expects to submit its application for approval in the third quarter of 2026.
In a statement by uniQure CEO Matt Kapusta:”Today’s announcement reflects the outcome we have worked toward throughout our continued regulatory engagement with FDA, and we are deeply grateful for FDA’s genuine commitment to addressing the unmet need of Americans living with Huntington’s disease. The FDA has agreed that our current clinical data can support a near-term BLA submission and has committed to work expeditiously with us to align on the design of the required confirmatory study. The consistency and strength of the clinical data generated to date give us great confidence in the product’s potential to make a meaningful difference for patients. We remain focused on bringing AMT-130 to patients and families as quickly and responsibly as possible in the US and globally.”
To find out more about Huntington’s Disease or help with getting support for the disease, visit their website: www.hdsa.org
Updated 6-19-26 to include quote from CEO uniQure CEO Matt Kapusta
Discover more from
Subscribe to get the latest posts sent to your email.
